42 articles for S Roy
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.
Merck Research Laboratories
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.
Merck Research Laboratories
Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.
Merck Research Laboratories
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.
Merck Research Laboratories
Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies.
Momenta Pharmaceuticals
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Merck Research Laboratories
Discovery of pyrazole carboxylic acids as potent inhibitors of rat long chain L-2-hydroxy acid oxidase.
Advinus Therapeutics
Discovery of a potent and selective small molecule hGPR91 antagonist.
Advinus Therapeutics
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
TBA
Potent and Selective Inhibitors of Long Chain l-2-Hydroxy Acid Oxidase Reduced Blood Pressure in DOCA Salt-Treated Rats.
TBA
Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
Merck Research Laboratories
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.
Universita` Di Pisa
Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
Merck Research Laboratories
A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Merck Research Laboratories
Bicyclic Peptide Library Screening for the Identification of Gαi Protein Modulators.
University of Bonn
Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.
Merck Frosst Centre For Therapeutic Research
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.
Bristol Myers Squibb
Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.
Csir-Indian Institute of Chemical Biology
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Csir-Indian Institute of Chemical Biology
Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.
Merck Frosst Centre For Therapeutic Research
Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
Csir-Indian Institute of Chemical Biology
Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
Merck
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.
Merck Research Laboratories
Activity-guided development of potent and selective toll-like receptor 9 antagonists.
Csir-Indian Institute of Chemical Biology
A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity.
Csir-Central Institute of Medicinal and Aromatic Plants (Csir-Cimap)
Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.
Csir-Indian Institute of Chemical Biology
Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.
Merck
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
Incyte
Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases
Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung
BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF
Beigene Switzerland
NOVEL BIPHENYL DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
Xi'An Xinton Pharmaceutcal Research
C3-carbon linked glutarimide degronimers for target protein degradation
C4 Therapeutics
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
Arena Pharmaceuticals
Novel Indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties.
Tumor Biology Center